Neogen/$NEOG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neogen
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Ticker
$NEOG
Sector
Primary listing
Employees
2,974
Headquarters
Website
Neogen Metrics
BasicAdvanced
$1.2B
-
-$5.03
1.79
-
Price and volume
Market cap
$1.2B
Beta
1.79
52-week high
$17.25
52-week low
$3.87
Average daily volume
5.6M
Financial strength
Current ratio
3.316
Quick ratio
1.623
Long term debt to equity
42.236
Total debt to equity
44.141
Interest coverage (TTM)
0.01%
Profitability
EBITDA (TTM)
119.862
Gross margin (TTM)
47.10%
Net profit margin (TTM)
-122.06%
Operating margin (TTM)
-0.19%
Effective tax rate (TTM)
3.62%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
0.01%
Return on equity (TTM)
-41.88%
Valuation
Price to revenue (TTM)
1.333
Price to book
0.58
Price to tangible book (TTM)
-2.95
Price to free cash flow (TTM)
-25.737
Free cash flow yield (TTM)
-3.89%
Free cash flow per share (TTM)
-0.214
Growth
Revenue change (TTM)
-3.20%
Earnings per share change (TTM)
11,469.70%
3-year revenue growth (CAGR)
19.28%
10-year revenue growth (CAGR)
12.20%
3-year earnings per share growth (CAGR)
123.89%
10-year earnings per share growth (CAGR)
31.03%
What the Analysts think about Neogen
Analyst ratings (Buy, Hold, Sell) for Neogen stock.
Bulls say / Bears say
Despite missing on revenue, Neogen’s adjusted EPS for Q3 was $0.10, well ahead of expectations for a $0.01 per share loss. This highlights the company’s operational discipline and cost control despite a tough economic environment (Reuters).
The recently completed sale of Neogen’s Cleaners & Disinfectants division is expected to bring in $100 million, which will be used to pay down debt—reducing net leverage and giving the company more financial flexibility (Reuters).
Analysts remain optimistic, with an average ‘Buy’ rating and a median 12-month price target of $15, suggesting the shares still have meaningful upside potential (Reuters).
Neogen’s Q3 revenue came in at $221 million, missing consensus estimates of $232.36 million, a 3.4% decline from the previous year. This points to ongoing weakness in the end markets and continued macroeconomic challenges (Reuters).
Moody’s has affirmed Neogen’s Ba3 Corporate Family Rating, but revised its liquidity outlook to negative, warning that the company’s debt/EBITDA ratio is likely to stay above 4x for the next 12–18 months, which increases credit risk (Reuters).
CEO John Adent will step down after eight years in the role, bringing leadership transition risk at a time of major strategic changes and operational headwinds (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Neogen Financial Performance
Revenues and expenses
Neogen Earnings Performance
Company profitability
Neogen News
AllArticlesVideos
NEOG Deadline: Rosen Law Firm Urges Neogen Corporation (NASDAQ: NEOG) Stockholders to Contact the Firm for Information About Their Rights
Business Wire2 days ago
NEOGEN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Neogen Corporation - NEOG
Business Wire3 days ago
Neogen Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NEOG
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neogen stock?
Neogen (NEOG) has a market cap of $1.2B as of September 15, 2025.
What is the P/E ratio for Neogen stock?
The price to earnings (P/E) ratio for Neogen (NEOG) stock is 0 as of September 15, 2025.
Does Neogen stock pay dividends?
No, Neogen (NEOG) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Neogen dividend payment date?
Neogen (NEOG) stock does not pay dividends to its shareholders.
What is the beta indicator for Neogen?
Neogen (NEOG) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.